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Summary
Objective: The FRZB gene codes for secreted frizzled-related protein 3 (sFRP3), a soluble antagonist of wnt signalling that is required for
maintaining cartilage integrity. Two common single nucleotide polymorphisms (SNPs) that code for the substitution of conserved arginine res-
idues have previously been identiﬁed in FRZB and found to be associated with osteoarthritis (OA). Functional studies revealed that the argi-
nine substitutions lead to a loss-of-function of sFRP3 activity. We set out to assess whether cis-acting polymorphism in the regulation of FRZB
expression exists, as this may be an additional mechanism through which sFRP3 activity could be modulated.
Methods: RNA was extracted from the articular cartilage chondrocytes of 25 individuals who had undergone joint replacement for OA and who
were heterozygous for one of the two FRZB SNPs. Allelic output was measured by single base extension in to the SNPs and deviations from
the expected 1:1 pattern were assessed using the ManneWhitney U test.
Results: Differential allelic expression was observed in six of the 25 individuals. However, the average fold difference in allelic expression in
the six was only 1.19.
Conclusions: The presence of a small degree of differential allelic expression in a low proportion (24%) of the individuals studied suggests that
polymorphism in FRZB cis-acting regulatory elements can be discounted as a major factor that could inﬂuence the development of OA.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The wnt pathway is employed in a diverse range of biolog-
ical systems including skeletal patterning and joint forma-
tion. Secreted frizzled-related protein 3 (sFRP3) acts as
a decoy receptor in the pathway and is expressed in the de-
veloping and mature skeleton, where it regulates chondro-
cyte maturation. It has been proposed that sFRP3 holds
articular chondrocytes in a pre-hypertrophic state through-
out life, thus helping to maintain normal function of the car-
tilage layer of the synovial joint1e3.
The FRZB gene on chromosome 2q32.1 codes for sFRP3
and we had previously identiﬁed two single nucleotide poly-
morphisms (SNPs) in FRZB4. The ﬁrst, a C to T transition in
exon 4, codes for the substitution of a conserved arginine
with tryptophan (Arg200Trp). The second, a C to G transver-
sion in exon 6, also codes for the substitution of a conserved
arginine, this time with a glycine (Arg324Gly). Functional
studies demonstrated that substituting the arginines signiﬁ-
cantly reduced the ability of sFRP3 to antagonise wnt signal-
ling in vitro. The exon 6 SNP was associated with hip
osteoarthritis (OA) in female Caucasians from the UK, as
was the haplotype coding for the substitution of both argi-
nines. A subsequent investigation by aNetherlands group re-
vealed an association between the exon 6 SNP and
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Received 21 March 2006; revision accepted 25 June 2006.90radiographic OA at multiple sites5 whilst a Belgium study re-
ported that the exon 4 SNP was at a signiﬁcantly greater fre-
quency in OA patients compared to osteoporotic patients6.
Most recently, a FRZB knockout mouse was reported to de-
velop an OA phenotype characterised by an enhanced loss
of articular surface proteoglycans7. Overall, these studies
have demonstrated the importance of sFRP3 in articular
jointetissue homeostasis and highlighted the increased OA
risk that the FRZB arginine substitutions confer.
The arginine substitutions represent a loss-of-function of
sFRP3. Another mechanism through which sFRP3 function
could be inﬂuenced would be through polymorphism in cis-
acting elements that regulate the expression of FRZB. It is
becoming increasingly apparent that many genes demon-
strate polymorphism in cis-elements, and that these can re-
sult in signiﬁcant changes in gene expression8. The
principal objective of this study was to establish whether
cis-regulatory polymorphisms exist in the FRZB gene. We
aimed to achieve this by measuring the allelic expression
of FRZB in the cartilage chondrocytes of individuals who
were heterozygote for the exon 4 or the exon 6 arginine
substitutions: if one allele produces more FRZB mRNA
than the other allele in a heterozygote then polymorphism
in a cis-acting regulatory element is implied.
Patients and methods
NUCLEIC ACID EXTRACTION
Articular cartilage was collected from 25 individuals un-
dergoing elective joint replacement surgery for primary
91Osteoarthritis and Cartilage Vol. 15, No. 1OA. Five individuals (four men and one woman) had under-
gone total hip replacement (THR) and 20 individuals (ﬁve
men and 15 women) had undergone total knee replacement
(TKR). The patients were UK Caucasians with an average
age at the time of surgery of 73 years (age range of
50e83 years). Ethical approval for the study was obtained
from appropriate ethics committees. Macroscopically nor-
mal articular cartilage was identiﬁed away from osteoar-
thritic lesions, removed from the joint and snap frozen in
liquid nitrogen within 2 h of the operation. The frozen carti-
lage was ground to a powder using the Retsch Mixermill
200 (Retsch Limited, Leeds) and the RNA was then ex-
tracted as previously described9. Both genomic DNA and
RNA were extracted from the same cartilage sample, the
genomic DNA being eluted in the ﬁrst RW1 wash.
GENOTYPING THE FRZB SNPS
The cartilage genomic DNA was genotyped for the
Arg200Trp and Arg324Gly SNPs by a polymerase chain re-
action (PCR)-restriction enzyme analysis, as previously
described4.
FRZB PROMOTER SNPS
The FRZB promoter was scanned for SNPs by database
searching and by direct DNA sequencing using the BigDye
Terminator v3.1 cycle sequencing kit (Applied Biosystems,
Foster City, USA).
DIFFERENTIAL ALLELIC EXPRESSION ANALYSIS
To distinguish the mRNA output from the two copies of
a gene a differential allelic expression analysis can be con-
ducted using a coding SNP for that gene10. We carried out
our analysis on individuals who were heterozygous for the
Arg200Trp SNP or the Arg324Gly SNP. In doing so we
were not assuming that the SNPs themselves are responsi-
ble for any observed differential allelic expression. Instead,
they simply enabled us to compare the mRNA contributed
by each allele to the RNA pool. The cartilage genomic
DNA was used to assess an individual’s genotype for the
SNPs. For a heterozygote, 2 mg of cartilage RNA was
used to synthesise cDNA using random hexamers (Super-
script First Strand Synthesis kit, Invitrogen). The region
of the cDNA containing the SNP of interest was ampliﬁed
by PCR. The PCR product then served as the template to
test for differential allelic expression by a single base exten-
sion reaction using the ABI Prism SNaPshot Multiplex kit
(Applied Biosystems, Foster City, USA). The reaction in-
volves the extension of a primer that is located immediately
upstream of the SNP of interest. The primer is extended into
the polymorphic site using ﬂuorescently labelled dideoxy
nucleotides (ddNTPs). Each ddNTP has a unique ﬂuores-
cent tag that enables the extension products from the two
alleles to be distinguished. This method has been described
in detail10. The ﬂuorescently labelled extension products
were separated by electrophoresis through acrylamide us-
ing an Applied Biosystems 3100 DNA Sequencer and the
data were analysed using Genemapper software to create
electropherograms that listed peak heights. Genomic DNA
was also subjected to single base extension to demonstrate
the peak pattern expected when both alleles are equally rep-
resented (i.e., a 1:1 ratio). This pattern was used to assess
whether a cDNA peak height ratio was different from the
genomic ratio that one would expect when both alleles are
expressing equally. Peak height ratios were derived from atleast 20 PCR reactions for the genomic DNA and at least
20PCR reactions for the cDNA. ThePCRand single base ex-
tension primer sequences can be obtained from the authors.
STATISTICAL ANALYSIS
The non-parametric ManneWhitney U test was used to
assess whether the peak height ratios obtained for an indi-
vidual’s cDNA were signiﬁcantly different from the peak
height ratios of the genomic DNA. A signiﬁcant difference
would imply differential allelic expression of FRZB for that
individual. Fold differences were obtained by dividing the
average peak height ratio of an individual’s cDNA by the av-
erage peak height ratio of the genomic DNA.
Results and conclusions
Fourteen of the 25 individuals were identiﬁed as hetero-
zygote at the Arg200Trp SNP and 11 as heterozygote at
the Arg324Gly SNP. The RNA of these 25 individuals was
extracted and allelic output was assessed. Six of the 25 in-
dividuals (24%) demonstrated differential allelic expression
at FRZB (Fig. 1). Four of the six were heterozygote at the
Arg200Trp SNP and two were heterozygote at the Arg324-
Gly SNP. Of the six individuals demonstrating differential al-
lelic expression, the greatest fold difference observed was
1.32 for individual 3: one FRZB allele was expressing
32% more mRNA than the other FRZB allele. The average
fold difference in allelic expression for the six individuals
was only 1.19.
To assess whether there was any correlation between
promoter polymorphism and differential allelic expression
(DAE) status the FRZB promoter was scanned for SNPs
and there absence or presence was then compared to pa-
tient DAE status. Three SNPs were identiﬁed in FRZB
(rs12469777, rs9288087 and rs4293535). There was no
correlation between SNP genotype and DAE status (data
not shown). This indicates that polymorphism in the FRZB
promoter does not inﬂuence allelic expression. It cannot
be ruled out that trans-acting factors present at an earlier
developmental stage could interact with the FRZB promoter
SNPs or other potential cis-regulatory elements causing
DAE; presently there is no evidence for this.
Our previous investigations had suggested that the sub-
stitution of conserved arginine residues at positions 200
and 324 of sFRP3 lead to a loss-of-function of this wnt an-
tagonist and are risk factors for OA4. This result has been
supported by other studies5e7. Our aim in this current inves-
tigation was to assess whether cis-acting polymorphism in
the regulation of FRZB expression exists as this may be
an additional mechanism through which sFRP3 activity
could be modulated. To achieve this we measured the con-
tribution each copy of FRZB makes to the chondrocyte RNA
pool in 25 individuals: if one copy is contributing signiﬁcantly
more FRZB RNA than the other copy in an individual then
polymorphism in a cis-acting regulatory element of FRZB
is implied. To distinguish the contribution from the two cop-
ies we exploited SNPs located in the coding region of the
gene. The two SNPs used were those responsible for the
arginine substitutions. As already stated, when using these
two SNPs our assumption was not that they themselves are
responsible for any observed differential allelic expression.
Instead, they simply enabled us to distinguish the RNA con-
tributed by each copy of FRZB.
We observed only a small degree of differential allelic ex-
pression, in less than one quarter of the individuals tested. It
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Fig. 1. The differential allelic expression analysis of FRZB. A comparison between genomic DNA and cDNA ratios assayed at SNP Arg200Trp
(individuals 1e5) and at SNP Arg324Gly (individuals 6e8). The genomic DNA columns for the two SNPs are labelled. Individuals 1e4 dem-
onstrated differential allelic expression at SNP Arg200Trp whereas individual 5 did not. Individuals 6 and 7 demonstrated differential allelic
expression at SNP Arg324Gly whereas individual 8 did not. P-values refer to the signiﬁcance test for differences between the cDNA ratios
and the genomic ratios and were calculated using the ManneWhitney U test. P-values <0.05 were considered signiﬁcant. Fold differences
were obtained by dividing the average peak height ratio for an individual’s cDNA by the average peak height ratio for the genomic DNA.is reasonable to state therefore that there is only a low level
of cis-acting polymorphism in the regulation of expression of
FRZB in articular cartilage chondrocytes. Unlike the FRZB
arginine substitutions, it would appear that regulatory poly-
morphism is not a major modulator of the activity of
sFRP3 and is an unlikely OA genetic risk factor.
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